In congruence with reports on KDM5B-associated therapy persistence5,16,17, we observed decreased drug susceptibility to MAPK signaling pathway inhibitor (MAPKi) treatment upon KDM5B upregulation irrespective of the melanoma cell line tested (Fig. 2a, right panel). Here, KDM5B is linked to melanoma.